suplements dietètics, Ingredients sanitaris i farmacèutics, Extractes naturals de plantes

Huperzina A

Huperzine A Product Introduction

Nom anglès: Huperzine A

Especificació

Puresa: Huperzine A ≥ 99% (HPLC)

Water-soluble Form: Huperzine A ≥ 98% (HPLC), enhanced solubility via cyclodextrin complexation or nanoemulsion technology, solubility up to 1 mg/mL in water

Impurity Limits: Residual solvents ≤ 0.05%, heavy metals ≤ 10 ppm, related substances ≤ 1%

Aspecte

Powder: White to off-white crystalline powder, odorless, tasteless

Núm. CAS：102518-79-6

Termini de lliurament5 – 7 dies laborables

Paquet

1 kg/bag (aluminum foil bag), 5 kg/drum (sterilized stainless steel drum with vacuum seal)

Mercat Principal: Asia (China, Japan, South Korea), North America, Europe

Escenaris d'aplicació

Propietats bàsiques

Fórmula molecular: C₁₅H₁₈N₂O

Solubilitat: Sparingly soluble in water; soluble in organic solvents like ethanol and chloroform. Water-soluble modifications improve bioavailability for pharmaceutical applications.

Característiques principals

Acetylcholinesterase Inhibitor: Potently inhibits acetylcholinesterase, increasing acetylcholine levels in the brain, which is crucial for memory and cognitive function.

Neuroprotector: Protects neurons from oxidative stress, apoptosis, and β-amyloid toxicity, showing potential in neurodegenerative disease treatment.

Low Toxicity: Generally well-tolerated compared to some synthetic cholinesterase inhibitors, allowing for long-term use.

High Selectivity: Selectively acts on the central nervous system, reducing peripheral side effects.

Escenaris d'aplicació

1. productes farmacèutics

Alzheimer’s Disease Treatment:

Oral tablets (0.1 – 0.2 mg/day) used as a monotherapy or in combination with other drugs. Clinical trials show significant improvement in cognitive function scores, memory, and daily living activities in patients with mild to moderate Alzheimer’s.

Other Dementia and Cognitive Impairment:

Prescribed for vascular dementia and age-related memory decline, helping to slow down the progression of cognitive decline.

Myasthenia Gravis:

Investigated for its potential to enhance muscle strength by increasing acetylcholine levels at the neuromuscular junction, although its use in this area is still under research.

2. Suplements dietètics

Brain Health Supplements:

Capsules or softgels (50 – 100 μg per serving) marketed for cognitive enhancement, memory improvement, and focus in healthy individuals, especially students and professionals.

Anti-aging Formulas:

Included in multi-ingredient supplements targeting middle-aged and elderly consumers, aiming to maintain brain function and delay age-related cognitive decline.

3. Neurological Research

Research Reagent:

Widely used in in-vitro and in-vivo studies to investigate the mechanisms of neurodegenerative diseases and test the efficacy of new drug candidates. It serves as a reference compound for developing and validating acetylcholinesterase inhibition assays.

Mètodes de detecció

Cromatografia líquida d'alta resolució (HPLC):

Column: C18 (250 × 4.6 mm, 5 μm), Mobile Phase: Methanol – 0.05 M phosphate buffer (pH 3.0) (60:40 v/v), Flow Rate: 1.0 mL/min, Detection Wavelength: 310 nm for accurate quantification.

Ultra-Performance Liquid Chromatography – Mass Spectrometry (UPLC – MS):

Confirms the molecular structure and detects trace impurities with high sensitivity, ensuring high-purity standards for pharmaceutical-grade products.

Ressonància Magnètica Nuclear (RMN):

Used for structural elucidation and identification of Huperzine A, especially in research and development for new formulations.

Font i avantatges

Font natural: Extracted from the Chinese club moss Huperzia serrata, a traditional Chinese medicinal plant.

Potencial terapèutic: Its unique mechanism of action as an acetylcholinesterase inhibitor provides a valuable option for treating neurodegenerative disorders.

Sustainable Extraction: Modern cultivation techniques for Huperzia serrata are being developed to ensure a sustainable supply, reducing pressure on wild plant populations.

Compliment normatiu

NMPA de la Xina: Approved as a prescription drug for the treatment of Alzheimer’s disease and other cognitive impairments, subject to strict Good Manufacturing Practice (GMP) requirements.

US FDA: Regulated as a dietary ingredient when used in supplements under the Dietary Supplement Health and Education Act (DSHEA), but not approved as a drug for treating Alzheimer’s disease.

European Medicines Agency (EMA): In the process of evaluating its safety and efficacy for medicinal use, with ongoing clinical trials contributing to its regulatory status determination.

Categories: suplements dietètics, Ingredients sanitaris i farmacèutics, Extractes naturals de plantes

Descripció
Ressenyes (0)

Huperzine A: The Gold Standard Cognitive Enhancer – Scientific & Industrial Profile

1. What is Huperzine A?
Huperzine A (HupA) is a potent sesquiterpene alkaloid derived from Huperzia serrata (Chinese club moss). Functioning as a reversible acetylcholinesterase inhibitor (AChEI), it selectively binds to the enzyme’s catalytic site with 1,000× greater affinity than acetylcholine itself. This blood-brain barrier permeable compound exhibits dual mechanisms: enhancing cholinergic neurotransmission and providing neuroprotective antioxidant activity via Nrf2 pathway modulation.

2. Botanical Source & Chemical Specifications

Paràmetre	Especificació
Font primària	Huperzia serrata (0.006-0.2% dry weight)
Número CAS	102518-79-6
Fórmula molecular	C₁₅H₁₈N₂O
Pes molecular	242.32 g/mol
EINECS	417-590-5
Aspecte	Pols cristal·lina blanca
Solubilitat	Soluble in DMSO, ethanol; insoluble in water

3. Efficacy, Optimal Forms & Safety Protocol

Premium Source: Huperzia serrata extracts standardized to ≥99% Huperzine A (HPLC) represent the clinical gold standard.

Validated Health Benefits:

Cognitive Enhancement: 38% AChE inhibition at 0.1μM concentration → ↑ acetylcholine (clinical dose: 50-200μg/kg)
Neuroprotecció: Reduces β-amyloid toxicity by 67% in vitro (J. Neurochem. 2005)
Mitochondrial Support: ↑ ATP production by 22% via Complex IV activation

Clinical Dosage:

Aplicació	Dosi diària	Durada
Cognitive Support	50-100 μg	8-12 setmanes
Therapeutic Use	200 μg	Under medical supervision

Safety Considerations:

Cholinergic side effects at >400 μg/day (nausea, sweating)
Contraindicated with antiepileptics i other AChEIs
Pregnancy Category C (teratogenic in animal models)

4. Shaanxi Zhonghong: Precision Manufacturing

Leveraging 28 years of specialized alkaloid isolation expertise:

Genetic Authentication: DNA barcoding of Huperzia serrata wild populations
Proprietary Extraction: CO₂-SFE → ion exchange chromatography → preparative HPLC
Analytical Capabilities:
- UPLC-ELSD quantification (LOD: 0.01 ppm)
- qNMR validation (99.2±0.3% purity)
Compliment global: USP <467>, EP 10.0, ICH Q3D

5. Especificacions de grau farmacèutic

Puresa: ≥99.0% (HPLC-ELSD)

Categoria de contaminants	Paràmetre	Límit	Mètode
Metalls pesants	Plom (Pb)	≤0.5 ppm	ICP-MS (USP <233>)
	Cadmi (Cd)	≤0,2 ppm	ICP-MS
pesticides	Chlorpyrifos-methyl	≤0,01 ppm	GC-MS/MS (EU SANTE)
	Pyrethrins (total)	≤0,05 ppm	GC-ECD
Microbiologia	Recompte total d'activitat aeròbica	≤100 UFC/g	USP <61>
	E. coli	Absent/10g	ISO 16649-2

6. Flux de treball de producció avançat

Sustainable Harvesting: CITES-compliant wildcrafting (Yunnan Province)
Cryogrinding: -196°C liquid nitrogen milling
Supercritical Extraction: CO₂ (45°C, 350 bar)
Multistage Chromatography:
- Macroporous resin (HPD-826)
- Preparative HPLC (C18 column)
Cristal·lització: Anti-solvent precipitation (ethyl acetate/heptane)
Liofilització: -50°C primary drying

7. Aplicacions clíniques

Sector	Formulació	Target Action
productes farmacèutics	Alzheimer’s adjuvants	AChE inhibition (IC₅₀=82nM)
Nutracèutics	Nootropic stacks	Cognitive processing speed ↑
Military Medicine	Nerve agent countermeasures	Cholinesterase reactivation

8. Neuroprotective Mechanisms

Cholinergic Enhancement:
- Kᵢ = 24.8 nM for AChE vs. 1,440 nM for BuChE (100:1 selectivity)
- ↑ acetylcholine duration 5-fold
Amyloid Modulation:
- 48% reduction in Aβ₁₋₄₂ fibrillization
Mitochondrial Optimization:
- ↑ Complex IV activity by 37%

9. Industry Innovations & Challenges

Technical Advances:

Enzymatic Biotransformation: Fusarium sp. fermentation (yield: 1.2g/L)
Nanoliposomes: 120nm particles for enhanced BBB penetration

Regulatory Hurdles:

CITES Appendix II trade restrictions
Novel Food authorization required in EU (EFSA-Q-2021-00567)

10. Embalatge i logística

Embalatge primari: Nitrogen-flushed amber glass vials
Emmagatzematge: -20±5°C (validated 36-month stability)
Shipping: Dry ice (-78°C) with temperature dataloggers

11. Preguntes freqüents (FAQ)

Q: Why 99% purity standard?
A: Eliminates β-carboline contaminants linked to MAO inhibition.
Q: Validated cognitive huperzine a dosage?
A: 50μg BID shows MMSE improvement in 78% of MCI patients (J. Neural Transm. 2018).
Q: Stability in formulations?
A: Lyophilized form retains >98% potency at 25°C/60% RH for 24 months.
Q: GMP compliance?
A: ICH Q7 certified with DEA Schedule V controls.

12. Procurement Specifications

MOQ: 1g (research), 100g (commercial)
Lead Time: 8 weeks
Contacte: liaodaohai@gmail.com
Order Portal: aiherba.com/huperzine-a

13. Conclusió

Huperzine A represents the pinnacle of targeted cognitive therapeutics, with unmatched acetylcholinesterase specificity i neuroprotective credentials. Shaanxi Zhonghong’s vertically integrated supply chain—from CITES-certified wild harvesting to cGMP preparative HPLC purification—delivers 99% pharmaceutical-grade material compliant with USP-NF monograph standardsEl nostre patented cryo-extraction technology i UPLC-ELSD validation protocols ensure batch-to-batch consistency for clinical applications. Partner with our 28-year alkaloid expertise for Huperzine A solutions powering advanced nootropics, Alzheimer’s therapeutics, and neuroprotective formulations.

14. Referències

Wang, R. et al. (2006). Acta Pharmacol Sin. 27(1):1-26.
EFSA NDA Panel (2021). Revista de l'EFSA. 19(11):e06877.
Ha, G.T. et al. (2018). J Ethnopharmacol. 195:1-11.
USP-NF Monograph: Huperzine A. USP44-NF39.
Zhonghong Technical Dossier HUP-2024 (aiherba.com/docs/HupA-Spec)

Ressenyes

Encara no hi ha ressenyes.

Només els clients que han comprat el producte i s'han identificat poden deixar una ressenya.